———–|———-|————|
| Aging & longevity |
Strong (IGF-1 elevation) |
Moderate |
| Body composition |
Strong (lean mass, fat loss) |
Moderate-Strong |
| Sleep quality |
Strong (pulsatile release) |
Moderate |
| Recovery & repair |
Strong |
Moderate |
| Metabolic health |
Strong |
Moderate |
| Bone density |
Moderate-Strong |
Moderate |
| Cognitive function |
Emerging research |
Emerging |
| Cardiac health |
Research interest |
Research interest |
Dosage Protocols for Research
Disclaimer: All dosage information is for research reference only. These compounds are not approved for human use.
CJC-1295 No DAC Dosage
| Protocol |
Dosage |
Frequency |
| Standard research |
100-200 mcg |
1-3x daily |
| With Ipamorelin stack |
100 mcg |
2-3x daily |
| Single daily dose |
200-300 mcg |
Before bed |
| Loading phase |
200 mcg |
3x daily (first week) |
CJC-1295 with DAC Dosage
| Protocol |
Dosage |
Frequency |
| Standard research |
1-2 mg |
Once weekly |
| Higher dose studies |
2-3 mg |
Every 5-7 days |
| Long-term studies |
1 mg |
Every 7-10 days |
Ipamorelin Dosage
| Protocol |
Dosage |
Frequency |
| Standard research |
200-300 mcg |
1-3x daily |
| With CJC-1295 stack |
100-200 mcg |
2-3x daily |
| Single daily dose |
300-500 mcg |
Before bed |
| Loading phase |
300 mcg |
3x daily (first week) |
The Standard CJC-1295 + Ipamorelin Stack
The most common research combination:
CJC-1295 No DAC: 100 mcg
Ipamorelin: 100-150 mcg
Frequency: 2-3 times daily
Timing: Morning, post-workout, and before bed
Cycle length: 8-12 weeks
IGF-1 testing: Baseline and at 4-6 weeks
Hanpro Peptides offers a convenient CJC-1295 + Ipamorelin blend for combined research protocols.
Side Effects Comparison
CJC-1295 Side Effects (Research Observations)
Common:
Injection site redness or irritation
Temporary water retention
Increased hunger (mild)
Fatigue or drowsiness (especially with DAC version)
Headaches (usually transient)
Less common:
Numbness or tingling (paresthesia)
Joint pain (at high doses)
Elevated liver enzymes (transient)
Decreased insulin sensitivity (transient)
Ipamorelin Side Effects (Research Observations)
Common:
Injection site discomfort
Headaches (mild, transient)
Increased appetite (less than GHRP-6)
Flushing or warmth
Water retention (mild)
Less common:
Nausea (at high doses)
Dizziness
Fatigue
Elevated prolactin (minimal compared to other GHRPs)
Key Difference in Side Effect Profiles
Ipamorelin is generally considered to have a cleaner side effect profile because:
It does not significantly stimulate cortisol or prolactin
It causes less appetite stimulation than GHRP-6
It has lower risk of desensitization with long-term use
It produces a more moderate, physiological GH increase
CJC-1295 vs Ipamorelin: Which to Choose?
Choose CJC-1295 If:
You want sustained GH elevation (with DAC version)
Research focuses on IGF-1 mediated effects
Less frequent dosing is preferred (DAC version)
Study involves body composition and recovery
You want to mimic natural pulsatile release (No DAC)
Choose Ipamorelin If:
You want a cleaner, more selective GH secretagogue
Minimizing prolactin/cortisol effects is important
Research involves metabolic and appetite regulation
You prefer a milder, more tolerable compound
Stacking with a GHRH analog for synergy
Most Research Uses Both:
The majority of contemporary growth hormone peptide research uses CJC-1295 (No DAC) + Ipamorelin together, as this combination provides the most physiological and effective GH stimulation.
How to Reconstitute and Store
Reconstitution Guide
Wipe vial stopper with alcohol swab
Inject bacteriostatic water (typical: 2mL for 5mg vial)
Swirl gently until dissolved — do not shake
Store in refrigerator at 2-8°C
Use within 30 days of reconstitution
Storage Guidelines
Lyophilized powder: -20°C freezer, 2+ years stability
Reconstituted solution: 2-8°C refrigerator, 30 days
Avoid: Freeze-thaw cycles, direct light, room temperature storage
BAC water preferred: Over sterile water for multi-dose vials
Use our Peptide Calculator for precise dosing volume calculations.
Purity and Quality Standards
When sourcing CJC-1295 and Ipamorelin for research:
HPLC purity: ≥98% (target >99%)
Mass spectrometry: Confirms correct sequence and molecular weight
Endotoxin testing: Essential for in vivo research
DAC verification: For CJC-1295 with DAC, confirm DAC conjugation
Certificate of Analysis: Should be available from supplier
Hanpro Peptides provides third-party tested CJC-1295 and Ipamorelin with full CoA documentation, ensuring research-grade quality.
Related Growth Hormone Peptides
Explore these additional GH-related research compounds:
Sermorelin Acetate — Original GHRH (1-29) peptide
GHRP-2 — Potent growth hormone secretagogue
GHRP-6 — GHS with strong appetite stimulation
Hexarelin — Potent GHRP with cardiac research interest
Tesamorelin — GHRH analog for visceral fat research
Frequently Asked Questions
Is CJC-1295 the same as Sermorelin?
No. While both are GHRH analogs, CJC-1295 is a modified version with increased stability and longer half-life. Sermorelin is the original 29-amino-acid fragment of natural GHRH.
Does Ipamorelin increase cortisol?
Compared to other GHRPs, Ipamorelin has minimal effect on cortisol and prolactin. This selectivity is one of its key advantages in research settings.
How long does it take to see IGF-1 increases?
In research studies, measurable IGF-1 elevation typically occurs within 2-4 weeks of consistent CJC-1295 + Ipamorelin administration, with peak effects at 6-8 weeks.
Can CJC-1295 with DAC be stacked with Ipamorelin?
Yes, but the timing differs. CJC-1295 with DAC is dosed once weekly, while Ipamorelin is dosed daily. Many researchers prefer CJC-1295 No DAC for stacking due to more predictable pulsatile release.
What is the best time to administer these peptides?
Common research timing includes: first thing in the morning (fasted), post-workout, and 30-60 minutes before bed. The before-bed dose leverages natural nocturnal GH release patterns.
*Disclaimer: This article is for educational and research informational purposes only. CJC-1295 and Ipamorelin are research-use-only compounds not approved for human or animal consumption. All dosage and protocol information is based on preclinical research and does not constitute medical advice.*
